The phrase "and the third evaluation" is correct and usable in written English.
It can be used when referring to a sequence of evaluations or assessments, specifically indicating the third one in that series.
Example: "After reviewing the first two evaluations, we will now discuss and the third evaluation."
Alternatives: "the third assessment" or "the third review".
The control group at the first evaluation included normal prepubertal children, and at the third evaluation it included 31 adolescents aged 14 16 years and 30 young adults aged 17 20 years of normal height and weight and spontaneous pubertal development.
The concordance rates between the students and echocardiographers in the subjective analysis of the LV function were 81.3% at the first evaluation, 96.9% at the second evaluation and 100% at the third evaluation (p < 0.001).
The concordance rates between the students and echocardiographers in the subjective analysis of LV function were 81.3% at the first evaluation, 96.9% at the second evaluation and 100% at the third evaluation (p < 0.001 for the 1st evaluation vs. the 3rd evaluation).
The means of the absolute differences between the students' and echocardiographers' EF measurements were 9.1% at the first evaluation, 8% at the second evaluation and 7% at the third evaluation (p = 0.6), and the medians were 8.8%, 6%and5.2%2%, respectively.
The means of the differences in the CI measurements were 1.31 L/min/m at the first evaluation, 1.29 L/min/m at the second evaluation and 0.56 L/min/m at the third evaluation (p = 0.001), and the medians were 1.1 L/min/m, 0.9 L/min/m and 0.5 L/min/m, respectively.
For the dIVC, we observed a concordance of 46.7% at the first evaluation, 90.3% at the second evaluation and 87.5% at the third evaluation (p = 0.004).
For the dIVC measurement, we observed a concordance of 46.7% at the first evaluation, 90.3% at the second evaluation and 87.5% at the third evaluation (p = 0.004).
Plasma IGF I was measured in all but 3 at diagnosis and in all at the third evaluation.
Serum IGF1 levels fell from 265±114% ULN at baseline to 138±88% at the first evaluation, on an average dose of 25 (10 40) mg/day, then to 119±70% ULN at the second evaluation, on an average dose of 33 (15 80) mg/day (Fig. 2D), and 87±17% ULN at the third evaluation, on an average dose of 37 (15 80) mg/day (Fig. 2G).
The first evaluation was the measurement model from the latent variable statistics, and the second evaluation was the structural model.
